A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer

Centocor, Inc.0 个研究点目标入组 131 人开始时间: 2012年4月30日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Inclusion Criteria
•- Confirmed cancer of the prostate
•- Evidence of metastatic disease
•- Have a life expectancy greater than 12 weeks
•- Have at least 4 weeks from previous major surgery to date of first study agent given
•- Have progressive hormone-refractory disease after orchiectomy or
•gonadotropin-releasing hormone analog and/or antiandrogen treatment within 6 months
•prior to the first study agent administration

•Exclusion Criteria
•- Have known Central Nervous System metastases (cancerous tumors that have spread to
•the brain from somewhere else in the body)
•- Had prior systemic non-hormonal therapy for hormone refractory prostate cancer
•- Have known Human Immunodeficiency Virus (HIV, a life-threatening infection which you
•can get from an infected person's blood or from having sex with an infected person)
•seropositivity or known hepatitis B or C infection
•- Have planned major surgery during the study
•- Have taken any over-the-counter (medicine that can be bought without a prescription)
•or herbal treatment for prostate cancer within 4 weeks prior to the first study
•treatment administration

发起方